Dapagliflozin at Discharge on Hospital Heart Failure Readmission

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT04249778

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04249778
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04249778. Randomized; double masking; primary purpose treatment. Start 2020-07-29 (actual); primary completion 2022-03-03 (actual). Results posted on 2023-03-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin at Discharge on Hospital Heart Failure Readmission
Condition
Heart Failure
Condition
Diabetes
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Emory University (class: other)

Record details

Record id
cardio:ct-nct04249778
Content hash
ca42047d42bced22a4a87e3fef4047b09cc42bd73baf9940f74b33ff040648da